Cochlear Ltd COH

Morningstar Rating
A$153.17 +0.61 (0.40%)
View Full Chart

Company Report

Cochlear: Profit Target Looks Too Ambitious

Cochlear reaffirmed fiscal 2027 guidance for low-single-digit constant-currency revenue growth and AUD 330 million to AUD 350 million in underlying net profit. Developed-market implant volumes grew at a mid-single-digit rate from July to October, in line with management's expectations.

Price vs Fair Value

COH is trading at a LOCK|y@%K>vM premium.
Price
A$152.56
Fair Value
z%p
Uncertainty
LOCK|C!%^
1-Star Price
LOCK|W.zL
5-Star Price
x<
Economic Moat
LOCK|Mk
Capital Allocation
LOCK|<H#FJmN

Bulls Say, Bears Say

Bulls

There are signs Cochlear is looking to expand beyond the hearing market with the investment in Nyxoah, a company focused on hypoglossal nerve stimulation therapy for the treatment of obstructive sleep apnea.

Bears

Growth in the cochlear implant market is becoming more costly to achieve, limiting the potential upside to earnings.

News

Trading Information

Previous Close Price
A$152.56
Day Range
A$151.30–153.53
52-Week Range
A$88.74–284.88
Bid/Ask
A$151.31 / A$153.17
Shares Outstanding
65.40M
Market Cap
A$10.02B
Volume/Avg
253,175 / 574,336

Key Statistics

Price/Earnings (Normalized)
29.67
Price/Sales
4.25
Dividend Yield (Trailing)
2.26%
Dividend Yield (Forward)
1.70%
Dividend Payment Schedule
Apr, Oct
Total Yield
2.26%

Company Profile

Cochlear is the leading cochlear implant device manufacturer, with around 60% global market share. Developed markets contribute 80% of group revenue, where cochlear implants are the standard of care for children with severe-to-profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2026, 49% of revenue came from the Americas, 34% from Europe, the Middle East, and Africa, and 16% from the Asia-Pacific segment.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Mid Core
Total Number of Employees
4,500

Competitors

Valuation

Metric
COH
RMD
DEMANT
Price/Earnings (Normalized)
29.6721.3228.33
Price/Book Value
5.735.886.50
Price/Sales
4.256.222.97
Price/Cash Flow
27.1218.9417.10
Price/Earnings
COH
RMD
DEMANT

Financial Strength

Metric
COH
RMD
DEMANT
Quick Ratio
1.191.540.54
Current Ratio
2.152.650.82
Interest Coverage
16.43—6.70
Quick Ratio
COH
RMD
DEMANT

Profitability

Metric
COH
RMD
DEMANT
Return on Assets (Normalized)
11.76%19.58%6.76%
Return on Equity (Normalized)
17.18%26.61%24.80%
Return on Invested Capital (Normalized)
15.41%22.99%9.75%
Return on Assets
COH
RMD
DEMANT

Medical Devices Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Abbott Laboratories
ABT
LOCK|&N&!#RLOCK|^@%M$181B
Medtronic PLC
MDT
LOCK|zh#gSyLOCK|f#S^$131B
Stryker Corp
SYK
LOCK|&TRLKhCFLOCK|j!N$121B
Boston Scientific Corp
BSX
LOCK|WCjFzPLOCK|rbfnz$62B
Edwards Lifesciences Corp
EW
LOCK|F!kgGm><LOCK|zMyfr$61B
GE HealthCare Technologies Inc Common Stock
GEHC
LOCK|qJzzyl^LOCK|Pr$37B
DexCom Inc
DXCM
LOCK|?lgp?wcLOCK|$>y%$31B
Koninklijke Philips NV ADR
PHG
LOCK|nZxLOCK|X?d$29B
Steris PLC
STE
LOCK|RxqD#wLOCK|RXKBc$25B
Zimmer Biomet Holdings Inc
ZBH
LOCK|b!d!cy<LOCK|Q!$19B

Sponsor Center